Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2021 – Lung Cancer
ASCO 2021 – Lung Cancer
Cost-Effectiveness of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC Patients
ASCO 2021 – Lung Cancer
Modeling of the ADAURA trial data showed that 3 years of adjuvant osimertinib was more cost-effective than placebo in
EGFR
-mutated non–small-cell lung cancer (NSCLC).
Read More ›
Utilization of Multigene Assays in Patients with NSCLC
ASCO 2021 – Lung Cancer
The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay.
Read More ›
Prior Authorization Tool Impacts Provider Adherence to Clinical Guidelines and Cost-Savings
ASCO 2021 – Lung Cancer
Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer.
Read More ›
Repeat Molecular Profiling Detects Actionable Genetic Alterations in Patients with Progressive Lung Cancer
ASCO 2021 – Lung Cancer
The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment.
Read More ›
Mobile Lung Cancer Screening in an Underserved Population Finds High Incidence of Concurrent Disease States
ASCO 2021 – Lung Cancer
A mobile computerized tomographic lung screening program detected a high number of incidental concurrent disease findings in a rural underserved high-risk population of heavy smokers.
Read More ›
Racial Disparities with Use of Chemotherapy plus Radiotherapy Among Patients with Stage III NSCLC
ASCO 2021 – Lung Cancer
Analysis of the National Cancer Database indicates that a lower proportion of black patients with locally advanced, stage III, non–small-cell lung cancer (NSCLC) receive concurrent chemotherapy plus radiotherapy compared with white patients.
Read More ›
IMpower010: Atezolizumab versus Best Supportive Care Post-Adjuvant Chemotherapy in Resected NSCLC
ASCO 2021 – Lung Cancer
Atezolizumab in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC) extends disease-free survival compared with best supportive care after receiving adjuvant chemotherapy.
Read More ›
Patient-Reported Outcomes from the Phase 2 CodeBreaK 100 Trial Evaluating Sotorasib in KRAS p.G12C–Mutated NSCLC
ASCO 2021 – Lung Cancer
Patients with pretreated
KRAS
p.G12C–mutated non–small-cell lung cancer (NSCLC) treated with sotorasib improved or maintained global health status/quality of life, physical functioning, and the severity of key lung cancer–related symptoms.
Read More ›
Racial Disparities in Follow-Up Care of Early-Stage Lung Cancer Survivors
ASCO 2021 – Lung Cancer
Significant racial disparities exist among lung cancer survivors in receipt of surveillance scans, guidance about follow-up care, and smoking cessation.
Read More ›
Health-Related Quality-of-Life Results of the KEYNOTE-598 Trial in Patients with Metastatic NSCLC with PD-L1 Tumor Proportion Score ≥50%
ASCO 2021 – Lung Cancer
Findings from KEYNOTE-598 detected no difference in health-related quality of life or time to true deterioration in lung cancer symptoms comparing treatment with pembrolizumab + ipilimumab versus pembrolizumab + placebo in patients with previously untreated metastatic non–small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score ≥50%.
Read More ›
Page 1 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us